在患有慢性斑块性牛皮的患者中使用0.3%的Roflumilast奶油:从DERMIS第三期试验中汇集PASI和PASI-HD的结果
Kim A Papp1,2, James Q Del Rosso3, Mark G Lebwohl4
1Probity Medical Research and Alliance Clinical Trials, 135 Union St E, Waterloo, ON, N2J 1C4, Canada. kapapp@probitymedical.com.
Dermatology and therapy
|October 24, 2025
概括
在临床试验中,Roflumilast奶油0.3%显著改善了斑块性牛皮. 牛皮区域和严重性指数-高歧视 (PASI-HD) 与标准PASI相比,提供了更准确的疾病改善评估.
科学领域:
- 皮肤病学 皮肤病学
- 临床药理学 临床药理学
背景情况:
- 罗夫米拉斯特奶油0.3%是一种选择性PDE4抑制剂,用于斑块性牛皮.
- 牛皮区域和严重性指数-高歧视 (PASI-HD) 为局部牛皮提供了比PASI更高的精度.
- 临床试验使用PASI和PASI-HD来评估罗米拉斯特的疗效.
研究的目的:
- 为了证明局部罗米拉斯特在牛皮患者的治疗效果.
- 为了比较PASI-HD与PASI在评估治疗结果中的疗效.
主要方法:
- 第三阶段,随机的,车辆受控试验 (DERMIS-1和DERMIS-2) 进行了8周.
- 年龄大于2岁,牛皮占身体表面积的2-20%的参与者每天服用一次0.3%的罗米拉斯特奶油.
- PASI和PASI-HD作为主要的临床终点措施.
主要成果:
- 与车辆相比,在第8周 (P < 0.0001) 治疗罗弗米拉斯特的患者显著增加,PASI (40.3%与6.5%) 和PASI-HD (59.9%与17.9%) 减少了≥75% (P < 0.0001).
- PASI-HD表现出比PASI更大的效果大小,特别是在更高的响应水平.
- 罗夫米拉斯特治疗导致疾病严重程度的统计学显著改善.
结论:
- 与车载治疗相比,局部使用的罗米拉斯特显著改善了牛皮的严重程度.
- 在牛皮的临床试验中,PASI-HD比PASI更准确地评估疾病变化.
相关概念视频
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
430
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
430
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
402
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
402
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.5K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.5K
01:19Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K